A pooled statistical analysis of randomized, controlled trials performed by Carbognin et al. indirectly compared the efficacy of PD-1 inhibitors in the treatment of NSCLC, advanced melanoma and genitourinary cancer. The gene discussed is PDCD1; the disease is melanoma.